GlassScriptPhysician profile
Danielle L Rogers
NPI 1245947845
$7,130.86
in general payments reported to CMS, 2019-2025
37 companies · $2,318 in 2025
The $2,318 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $209 · 2023: $1,848 · 2024: $2,756 · 2025: $2,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,922.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,153.75 | 2023-2025 | |
| Lilly USA, LLC | $760.72 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $651.59 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $612.71 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Phathom Pharmaceuticals, INC. | $399.49 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $387.57 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $352.48 | 2022-2025 | |
| Amgen INC. | $315.76 | 2023-2025 | Evenity, Prolia, Otezla |
| E.R. Squibb & Sons, L.L.C. | $313.88 | 2023-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $255.91 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $217.72 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $168.00 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $163.16 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $158.70 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $147.22 | 2023-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $143.71 | 2023-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $102.80 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $81.14 | 2022-2025 | Gvoke Hypopen |
| Radius Health, INC. | $72.64 | 2023-2025 | Tymlos |
| Dexcom, INC. | $64.95 | 2023-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $62.08 | 2023 | Gemtesa |
| Lundbeck LLC | $58.18 | 2023-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $51.50 | 2024 | Fanapt |
| Merck Sharp & Dohme LLC | $49.67 | 2023-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $42.27 | 2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $40.99 | 2024 | Trintellix |
| Axsome Therapeutics, INC. | $39.98 | 2023 | Auvelity |
| Scilex Pharmaceuticals INC. | $37.90 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.03 | 2023-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.96 | 2023-2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $30.15 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $29.32 | 2023 | Heplisav-B |
| Mylan Specialty L.P. | $22.36 | 2024 | Yupelri |
| Organon LLC | $22.12 | 2025 | Nexplanon |
| Amneal Pharmaceuticals LLC | $18.50 | 2025 | Unithroid |
| Ibsa Pharma INC. | $16.47 | 2023 | Tirosint, Licart |
| Painteq LLC | $14.48 | 2024 | Painteq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.